Heparin Market Size, Share and Forecast 2019-2025
A significant prevalence of venous thromboembolism and CVD (cardiovascular disease) is the major factor in promoting the growth of the global heparin market. In 2018, the Centre for Disease Control and Prevention (CDC ) published a report in which it stated that more than 900,000 people only in the US are affected by deep vein thrombosis and pulmonary embolism every year. More than 18 million people die across the globe due to cardiovascular disorder this shows an immense opportunity for the heparin market to grow as heparin is the primary drug used as an anticoagulant used to prevent blood clotting.
Heart diseases such as CVD and stroke; among other heart diseases are
the leading causes of mortalities across the globe. According to the CDC, every
40 seconds, an individual in the US has a heart attack. In addition, around
805,000 Americans have a heart attack every year. According to the WHO,
around 17.9 million fatalities occur due to CVD in 2016, representing around
31% of global fatalities. Amongst these fatalities, around 7.4 million were due
to CHD and approximately 6.7 million were due to stroke. By 2030, it has been
projected that CVDs would be responsible for approximately 23.6 million
mortalities across the globe. This growing prevalence of CVD induced the demand
for the anticoagulant drug which will contribute to the heparin market.
A full
Report of Heparin Market is Available at: https://www.omrglobal.com/industry-reports/heparin-market
Global
Heparin Market Segmentation
·
Unfractionated
Heparin
·
Ultra-Low
Molecular Weight Heparin (ULMWH)
·
Low
molecular weight Heparin (LMWH)
By Route of
Administration
·
Intravenous
·
Subcutaneous
By
Application
·
Atrial
Fibrillation & Heart Attack
·
Coronary
Heart Disease
·
Pulmonary
Embolism (PE)
·
Deep
Vein Thrombosis (DVT)
·
Others
Global
Heparin Market – Segment by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of The World
Company
Profiles
·
B Barun
Melsungen AG
·
Baxter
International Inc.
·
Eisai
Co. Ltd.
·
F.
Hoffman-La Roche Ltd.
·
Fresenius
Kabi AG
·
GlaxoSmithKline
plc
·
Hebei
Changshan Biochemical Pharmaceutical Co. Ltd.
·
Hikma
Pharmaceuticals PLC
·
Leo
Pharma A/S
·
Mylan
N.V.
·
Nanjing
Jianyou Biochemical Pharmaceutical Co. Ltd.
·
Novartis
AG
·
Opocrin
S.P.A
·
Pfizer
Inc.
·
Sanofi
S.A.
·
Syntex
S.A.
Reasons for Buying from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data, Request for
Report Customization @ https://www.omrglobal.com/report-customization/heparin-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
For
More Information, Visit Orion Market Research
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment